## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.0% in mid entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Caution: MRS_5 (-0.7%) diverging from MRS_20, watch for reversal. Outperforming sector by 6.1%. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($553.01)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Ulta Beauty Counters Rivals With Advantages in Product Selection, Stores, and Loyalty**
- Source: Morningstar | 20251210T220834 | Bullish | Relevance: 98%
- Ulta Beauty maintains a narrow economic moat through its strong brand, extensive product selection, and a successful loyalty program with over 45 million members. The company has significantly increased its revenue and store count over the past decade, effectively competing against both mall-based retailers and e-commerce giants like Amazon. Ulta's strategy leverages in-store experiences, salons, and promotions to encourage frequent customer visits and drive market share.

**2. Mia Young Named SVP of Cosmetics at Ulta Beauty**
- Source: WWD | 20251211T050434 | Bullish | Relevance: 98%
-  Mia Young has been appointed Senior Vice President of Cosmetics at Ulta Beauty, a strategic hire by chief merchandising and digital officer Lauren Brindley to boost the company's growth in beauty. Young, with over 20 years of experience in brand development from Tatcha and Hourglass, will oversee fragrance, makeup, and private label categories. Her role is crucial in defining Ulta's brand assortment and capitalizing on growing segments like fragrance, contributing to the retailer's global expansion goals.

**3. Is Ulta Beauty Stock Outperforming the Dow?**
- Source: Barchart.com | 20251211T113834 | Bullish | Relevance: 98%
-  Ulta Beauty Inc. (ULTA) has significantly outperformed the Dow Jones Industrials Average ($DOWI) over the past three months, six months, and the last 52 weeks. The company's strong performance is attributed to enhanced in-store experiences, an expanding loyalty program, exclusive brand launches, and robust e-commerce growth, while analysts maintain a "Moderate Buy" rating with a potential upside.

**4. Ulta Beauty (ULTA) Valuation Check After Q3 Earnings Beat and Upgraded Full-Year Guidance**
- Source: Yahoo Finance | 20251210T231856 | Bullish | Relevance: 98%
- Ulta Beauty (ULTA) exceeded expectations in its Q3 earnings, beating sales and earnings while also increasing full-year guidance, which boosted the stock's outlook. Despite a significant 40% year-to-date share price return and a 120% five-year total shareholder return, the stock is currently trading around analyst targets. While a narrative fair value suggests it's "ABOUT RIGHT" at $603 due to growth potential, a price-to-earnings lens indicates it's expensive at 22.5 times earnings compared to a 17.9 fair ratio.

**5. Earnings, Guidance, and Inflows Send Ulta Beauty Skyward**
- Source: FXEmpire | 20251210T112803 | Bullish | Relevance: 98%
- Ulta Beauty (ULTA) shares have surged significantly since 2010 due to strong bullish outlier inflows, excellent third-quarter fiscal 2025 results, and positive annual guidance. The company's robust sales, earnings growth, and institutional buying support suggest continued upward momentum for the stock. Ulta Beauty has consistently been a top-rated stock at MoneyFlows, indicating strong buy pressure and growing fundamentals.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- New product launch cycle could drive revenue acceleration.

### Fundamentals

PEG ratio 2.42 elevated, pricing in significant growth expectations. Forward P/E 21.1x stretched relative to 10% growth. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.6B |
| Beta | 0.87 |
| 52W Range | $309.01 - $611.90 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.42 |
| Forward P/E | 21.1 |
| Current P/E | 23.3 |
| YoY Growth | 10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 11.3% to 7.0% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 9.3% shows strong absolute momentum above own 20MA. Outperforming sector by 6.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (8.02), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.03% (CS: 86) | Strong |
| RSI_14 | 66.3 | Neutral |
| MACD Histogram | 8.02 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.264x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $593.41
- **Stop Loss:** $553.01 (6.8% risk)
- **Target:** $654.01 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 34
- **Position Value:** $20,175.94
- **Portfolio %:** 20.18%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.7% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*